Integral Diagnostics (ASX:IDX) Financial Strength: 3 (As of Dec. 2025) — 25% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IDX Integral Diagnostics Ltd ASX:IDX
68 GF Score
Price A$2.28
GF Value A$2.78
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Integral Diagnostics Financial Strength?

Integral Diagnostics ASX:IDX +1.33% 68 Financial Strength is 3 as of Dec. 2025, which is 25% below its 10-year median of 4.00. GuruFocus rates ASX:IDX with a GF Score™ of 68/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Integral Diagnostics has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Integral Diagnostics Ltd displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Integral Diagnostics's Interest Coverage for the quarter that ended in Dec. 2025 was 1.97. Integral Diagnostics's debt to revenue ratio for the quarter that ended in Dec. 2025 was 0.76. As of today, Integral Diagnostics's Altman Z-Score is 1.12.


Integral Diagnostics  (ASX:IDX) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Integral Diagnostics has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Integral Diagnostics Financial Strength Related Terms


ASX:IDX vs TMO, DHR, IDXX: Financial Strength Comparison

For the Diagnostics & Research subindustry, Integral Diagnostics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integral Diagnostics Financial Strength vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Financial Strength distribution charts can be found below:

* The bar in red indicates where Integral Diagnostics's Financial Strength falls into.


ASX:IDX
68GF Score
Integral Diagnostics Ltd ASX:IDX
Financial Strength is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integral Diagnostics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Integral Diagnostics's Interest Expense for the months ended in Dec. 2025 was A$-16.9 Mil. Its Operating Income for the months ended in Dec. 2025 was A$33.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$581.7 Mil.

Integral Diagnostics's Interest Coverage for the quarter that ended in Dec. 2025 is

Interest Coverage=-1*Operating Income (Q: Dec. 2025 )/Interest Expense (Q: Dec. 2025 )
=-1*33.312/-16.869
=1.97

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Integral Diagnostics Ltd interest coverage is 2.86, which is low.

2. Debt to revenue ratio. The lower, the better.

Integral Diagnostics's Debt to Revenue Ratio for the quarter that ended in Dec. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(19.709 + 581.677) / 786.958
=0.76

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Integral Diagnostics has a Z-score of 1.12, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 1.12 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Financial Strength →
What does a Financial Strength of 3 mean?
Integral Diagnostics (ASX:IDX) has a Financial Strength of 3 as of Dec. 2025. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Integral Diagnostics and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Integral Diagnostics' Financial Strength has ranged from 3.00 to 5.00.
Is Integral Diagnostics' Financial Strength too high?
Integral Diagnostics' current Financial Strength of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. Overall, Integral Diagnostics has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Financial Strength compare to TMO and DHR?
Integral Diagnostics' Financial Strength of 3 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Integral Diagnostics' own Financial Strength has ranged from 3.00 to 5.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Medical Diagnostics & Research company?
A good Financial Strength depends on the Medical Diagnostics & Research industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Integral Diagnostics and its competitors. Integral Diagnostics's current Financial Strength is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.28 — trading 18% below its estimated fair value. The current Financial Strength is 3, which is 25% below median its 10-year median of 4.00. Integral Diagnostics' overall GF Score™ is 68/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current Financial Strength is 3 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?

Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued. The current stock price of A$2.28 is trading 18% below its estimated GF Value™ of A$2.78. GuruFocus considers Integral Diagnostics to be Modestly Undervalued.

Key valuation signals for ASX:IDX:

  • Financial Strength: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: A$2.78 vs. price of A$2.28 (18% below fair value)
  • GF Score™: 68/100 with 9 warning signs

No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integral Diagnostics Business Description

Other Exchanges ITGDF:USA
Address 288 Victoria Parade, Level 2, Melbourne, VIC, AUS, 3002
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
68GF Score

Get the complete analysis for ASX:IDX

Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.28
Price
A$2.78
GF Value